

Ref: FOI/2022/8651

Date Received: 30th January 2023

Response Due: 27th February 2023

Date:

Dear Sir/Madam

You asked:

Please see below a Freedom of Information request made by OPEN Health. Please answer the questions with regards to NHS patients, i.e., excluding patients that receive treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

- 1. How many patients have received treatment with venetoclax for AML during the past 24 months? Note: please provide data for the most recent 24-month period available via your prescribing/management system.**

Answer: 13

- 2. What is the average daily dose (mg) for AML patients receiving venetoclax during the past 24 months?**

Answer: 100mg

- 3. What is the average cycle intensity (days) for AML patients receiving venetoclax during the past 24 months? (e.g., 14-day cycles, 21-day cycles, other length of cycle)**

Answer: *28 days cycles with 14 to 28 days course length of venetoclax*

- 4. What is the average duration of treatment (months) for AML patients receiving venetoclax during the past 24 months?**

Answer: 5 cycle (range 1 to 16)

Patients with chronic lymphocytic leukaemia (CLL)

5. Please complete the table below based on the number of patients that have received venetoclax in each of the specified regimens for CLL in the last 24 months.

Note: please provide data for the most recent 24-month period available via your prescribing/management system.

	Treatment regimens		
	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Total number of CLL patients receiving this treatment regimen during the past 24 months	<5	<5	5
Average daily maintenance dose (mg) of venetoclax for patients initiated on this regimen during the past 24 months*	400mg	N/A	N/A
Average duration (months) of venetoclax treatment for patients initiated on this regimen during the past 24 months	7.75	N/A	17.4 (Range 5 – 24)

We would like to understand the average daily dose of venetoclax in CLL patients during maintenance treatment i.e. after the initial 8-week period during which patients would be receiving a titration regimen.

Patients with acute myeloid leukaemia (AML) or chronic lymphocytic leukaemia (CLL)

6. Please complete the table below with the average number of venetoclax 10 mg x 14 tablet packs† used per AML or CLL patient receiving each of the specified regimens during the past 24 months.

	AML treatment regimen	CLL treatment regimens		
	Venetoclax + azacitidine	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Average number of venetoclax 10 mg x 14 tablet packs used per patient in each treatment regimen during the past 24 months	0.2 of a pack	1 x 14 x 10mg per patient	N/A	1 x 14 x 10mg per patient

†Note: There are five different pack sizes of venetoclax available in the UK:

- **Pack 1: venetoclax 10 mg x 14 tablets**
- **Pack 2: venetoclax 50 mg x 7 tablets**
- **Pack 3: venetoclax 100 mg x 7 tablets**
- **Pack 4: venetoclax 100 mg x 14 tablets**
- **Pack 5: venetoclax 100 mg x 112 tablets**

7. Please can you share your prescribing protocol(s) for venetoclax in AML and CLL?

Answer: Please find Protocols attached.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 28 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Sanjay Arya
Medical Director

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111